5 Unstoppable Stocks That Could Double Your Money

3. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon reported its financial results for the full year 2025, highlighting the clinical advancement of its anti-CD40L antibody, tegoprubart. The company announced that tegoprubart received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation, adding to its existing designations for pancreatic islet cell transplantation and ALS.

Clinical data from a Phase 1b long-term extension study in kidney transplantation showed a favorable safety profile over 24 months, with no reported graft losses or rejection episodes and an improvement in mean estimated glomerular filtration rate. In a University of Chicago Medicine-led study, tegoprubart showed promising results in treating type 1 diabetes via islet transplantation. For 2026, Eledon anticipates receiving FDA guidance for a Phase 3 trial in kidney transplantation and plans to initiate new investigator-led studies in liver and islet cell transplantation.

Financial results for 2025 reflected increased investment in clinical programs, with R&D expenses rising to $66.3 million from $52 million in the previous year. This increase was driven by expanded trial activities, manufacturing scale-up, and additional personnel. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) reported a net loss of $45.6 million for the year, which included a $33.4 million non-cash gain from changes in the fair value of warrant liabilities.

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that targets the CD40L pathway to develop ALS treatments and therapies to prevent organ transplant rejection. The company’s lead candidate, tegoprubart, is an anti-CD40L IgG1 antibody.